Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke J Laffin

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 4, 2026
Invivo gene editing for lipid management: An early perspective from ANGPTL3-targeted CRISPR-Cas9 therapyLuke J Laffin, Steven E Nissen
Trends in Cardiovascular Medicine|January 21, 2023
Lp(a) - an overlooked risk factorLuke J Laffin, Steven E Nissen
Seminars in Nephrology|May 13, 2015
Endothelin antagonism and hypertension: an evolving targetLuke J Laffin, George L Bakris
Current Cardiology Reports|April 23, 2015
Update on blood pressure goals in diabetes mellitusLuke J Laffin, George L Bakris
European Journal of Preventive Cardiology|June 14, 2019
The SPRINT Trial Score web calculatorLuke J Laffin, Francis J Alenghat
Journal of the American College of Cardiology|April 26, 2023
Reply: The Nuance of Studying and Prescribing SupplementsLuke J Laffin, Steven E Nissen
Current Cardiology Reports|August 4, 2022
Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood PressureJonathan D Ravid, Luke J Laffin
Current Opinion in Pharmacology|December 27, 2014
Hypertension and new treatment approaches targeting the sympathetic nervous systemLuke J Laffin, George L Bakris
Current Hypertension Reports|June 2, 2016
Renal Denervation: a Field in FluxLuke J Laffin, George L Bakris
Plos Medicine|February 9, 2026
Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoptionLuke J Laffin, Steven E Nissen
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 4, 2026
Invivo gene editing for lipid management: An early perspective from ANGPTL3-targeted CRISPR-Cas9 therapyLuke J Laffin, Steven E Nissen
Trends in Cardiovascular Medicine|January 21, 2023
Lp(a) - an overlooked risk factorLuke J Laffin, Steven E Nissen
Seminars in Nephrology|May 13, 2015
Endothelin antagonism and hypertension: an evolving targetLuke J Laffin, George L Bakris
Current Cardiology Reports|April 23, 2015
Update on blood pressure goals in diabetes mellitusLuke J Laffin, George L Bakris
European Journal of Preventive Cardiology|June 14, 2019
The SPRINT Trial Score web calculatorLuke J Laffin, Francis J Alenghat
Journal of the American College of Cardiology|April 26, 2023
Reply: The Nuance of Studying and Prescribing SupplementsLuke J Laffin, Steven E Nissen
Current Cardiology Reports|August 4, 2022
Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood PressureJonathan D Ravid, Luke J Laffin
Current Opinion in Pharmacology|December 27, 2014
Hypertension and new treatment approaches targeting the sympathetic nervous systemLuke J Laffin, George L Bakris
Current Hypertension Reports|June 2, 2016
Renal Denervation: a Field in FluxLuke J Laffin, George L Bakris
Plos Medicine|February 9, 2026
Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoptionLuke J Laffin, Steven E Nissen
Pageof 9